Mushroom workers' lung

Summary

Mushroom workers’ lung (MONDO:0005865) is a disease. A subtype of hypersensitivity pneumonitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mushroom workers’ lung
Mondo ID	MONDO:0005865
DOID	DOID:2708
SNOMED CT	52333004
UMLS	C0155889
MedGen	102344
GARD	0024246
Is cancer (heuristic)	no

Also known as: bunashimeji worker’s lung · mushroom workers lung · pholiota worker’s lung · pleurotus worker’s lung · shiitaki worker’s lung · shimeji worker’s lung

Disease family

This is a subtype of hypersensitivity pneumonitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › allergic respiratory disease › hypersensitivity pneumonitis › mushroom workers’ lung

Related subtypes (13): ventilation pneumonitis, bagassosis, farmer’s lung disease, malt worker’s lung, cork-handlers’ disease, maple bark strippers’ lung, bird fancier’s lung, sick building syndrome, hypersensitivity pneumonitis, familial, idiopathic chronic eosinophilic pneumonia, house allergic alveolitis, non-fibrotic hypersensitivity pneumonitis, fibrotic hypersensitivity pneumonitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.